Published in Blood on March 22, 2010
Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis (2013) 2.99
A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum (2012) 1.60
Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol (2013) 1.13
Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis (2016) 0.96
Management of patients with hepatitis C infection and renal disease. World J Hepatol (2015) 0.95
Hepatitis C virus infection and mixed cryoglobulinemia. Clin Dev Immunol (2012) 0.94
Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. Clin Dev Immunol (2012) 0.93
Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol (2012) 0.92
Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer. World J Hepatol (2015) 0.90
Hepatitis C virus infection in nephrology patients. J Nephropathol (2013) 0.86
Hepatitis C virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of hepatitis C virus infection. Hepat Mon (2010) 0.85
Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy. Case Reports Immunol (2015) 0.85
Cutaneous manifestations of hepatitis C in the era of new antiviral agents. World J Hepatol (2015) 0.85
Current treatment of hepatitis C-associated rheumatic diseases. Arthritis Res Ther (2012) 0.84
Hepatitis C virus, cryoglobulinemia, and kidney: novel evidence. Scientifica (Cairo) (2012) 0.83
Interferon-based therapy for chronic hepatitis C: current and future perspectives. Hepat Mon (2010) 0.83
Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia. Am J Gastroenterol (2017) 0.82
B cell activating factor (BAFF) in the natural history of chronic hepatitis C virus liver disease and mixed cryoglobulinaemia. Clin Exp Immunol (2012) 0.80
New insights into HCV-related rheumatologic disorders: A review. J Adv Res (2016) 0.79
The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review. Clin Exp Med (2016) 0.78
An additional line of therapy with pegylated interferon and ribavirin after rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia and indolent non-Hodgkin's lymphoma previously treated with interferon. Blood Transfus (2011) 0.78
Molecular signature in HCV-positive lymphomas. Clin Dev Immunol (2012) 0.78
The place of immunotherapy in the management of HCV-induced vasculitis: an update. Clin Dev Immunol (2012) 0.76
[Neurological manifestations of vasculitis and primary central nervous system vasculitis]. Z Rheumatol (2012) 0.76
Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience. Arthritis Res Ther (2017) 0.75
Activation-induced cytidine deaminase in B cells of hepatits C virus-related cryoglobulinaemic vasculitis. Clin Exp Immunol (2015) 0.75
Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy. J Clin Transl Hepatol (2016) 0.75
Benign and Malignant Hematological Manifestations of Chronic Hepatitis C Virus Infection. Int J Prev Med (2014) 0.75
Hepatitis C Therapy in Renal Patients: Who, How, When? Infect Dis Ther (2016) 0.75
Thymic stromal lymphopoietin in hepatitis C virus-related cryoglobulinemic vasculitis: gene expression level and protein distribution. Arthritis Res Ther (2015) 0.75
Hepatitis C virus and neurological damage. World J Hepatol (2016) 0.75
Managing refractory cryoglobulinemic vasculitis: challenges and solutions. J Inflamm Res (2017) 0.75
A Rare Case of Hepatitis C-Associated Cryoglobulinemic Duodenal Vasculitis. ACG Case Rep J (2016) 0.75
Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet (2005) 2.95
Variation in genes encoding for interferon λ-3 and λ-4 in the prediction of HCV-1 treatment-induced viral clearance. Liver Int (2013) 2.07
Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist (2012) 1.76
Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood (2002) 1.58
HCV-associated B cell clonalities in the liver do not carry the t(14;18) chromosomal translocation. Hepatology (2005) 1.57
Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clin Exp Rheumatol (2012) 1.41
H. pylori infection and gastric cancer: state of the art (review). Int J Oncol (2012) 1.32
Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab (2009) 1.30
Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev (2011) 1.26
Antibody production and in vitro behavior of CD27-defined B-cell subsets: persistent hepatitis C virus infection changes the rules. J Virol (2006) 1.18
Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus. Gastroenterology (2012) 1.12
Angiogenesis and anti-angiogenesis in hepatocellular carcinoma. Cancer Treat Rev (2006) 1.10
Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med (2013) 1.09
B-cell frequency in hepatitis C virus-related mixed cryoglobulinemia. Hepatology (2013) 1.06
High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. Ann Surg Oncol (2014) 1.05
Extrasalivary lymphoma development in Sjögren's syndrome: clonal evolution from parotid gland lymphoproliferation and role of local triggering. Arthritis Rheum (2003) 1.05
Identification of novel chimpanzee MHC class I and II alleles using an improved sequence-based typing strategy. Hum Immunol (2006) 1.04
Identification of the novel Kawasaki 2014 GII.17 human norovirus strain in Italy, 2015. Euro Surveill (2015) 1.04
Cytokines and HCV-related disorders. Clin Dev Immunol (2012) 1.02
Intrahepatic B cell clonal expansions and extrahepatic manifestations of chronic HCV infection. Eur J Immunol (2004) 1.02
Community-wide outbreak of haemolytic uraemic syndrome associated with Shiga toxin 2-producing Escherichia coli O26:H11 in southern Italy, summer 2013. Euro Surveill (2016) 1.00
Barrett's esophagus and esophageal cancer: an overview. Int J Oncol (2012) 0.99
Control of hepatitis A by universal vaccination of adolescents, Puglia, Italy. Emerg Infect Dis (2008) 0.97
Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage. J Immunol (2009) 0.97
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. Lung Cancer (2013) 0.95
Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-kappaB pathway as a target for new therapeutic strategies. Leuk Lymphoma (2008) 0.95
Hepatitis C virus infection and mixed cryoglobulinemia. Clin Dev Immunol (2012) 0.94
PPAR signaling pathway and cancer-related proteins are involved in celiac disease-associated tissue damage. Mol Med (2010) 0.94
Norovirus gastroenteritis general outbreak associated with raw shellfish consumption in south Italy. BMC Infect Dis (2004) 0.93
Hepatitis C virus, B-cell proliferation and lymphomas. Leuk Lymphoma (2002) 0.93
Bone metastases in hepatocellular carcinoma: an emerging issue. Cancer Metastasis Rev (2014) 0.93
Antibody V(h) repertoire differences between resolving and chronically evolving hepatitis C virus infections. PLoS One (2011) 0.91
Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents. J Infect (2013) 0.91
Human immunodeficiency virus-associated precursor T-lymphoblastic leukemia/lymphoblastic lymphoma: report of a case and review of the literature. Hum Pathol (2009) 0.91
(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Eur J Nucl Med Mol Imaging (2015) 0.90
Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas. Br J Haematol (2009) 0.90
Impact of Cryoglobulinemic Syndrome on the Outcome of Chronic Hepatitis C Virus Infection: A 15-Year Prospective Study. Medicine (Baltimore) (2013) 0.90
Clinical relevance of Mycoplasma pneumoniae macrolide resistance in children. J Clin Microbiol (2012) 0.89
Chronic exposure to 50Hz magnetic fields causes a significant weakening of antioxidant defence systems in aged rat brain. Int J Biochem Cell Biol (2008) 0.89
Precancerous colorectal lesions (Review). Int J Oncol (2013) 0.89
Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas. J Hepatol (2008) 0.88
Analysis of aberrant somatic hypermutation (SHM) in non-Hodgkin's lymphomas of patients with chronic HCV infection. J Pathol (2005) 0.88
B cells and HCV: an infection model of autoimmunity. Autoimmun Rev (2009) 0.87
Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: bases for improved immunotherapy. Int J Cancer (2008) 0.87
Hepatitis C virus-induced oxidative stress and mitochondrial dysfunction: a focus on recent advances in proteomics. Proteomics Clin Appl (2010) 0.86
Undifferentiated nasopharyngeal carcinoma from a nonendemic area: protective role of HLA allele products presenting conserved EBV epitopes. Int J Cancer (2009) 0.86
Increased iNOS activity in vascular smooth muscle cells from diabetic rats: potential role of Ca(2+)/calmodulin-dependent protein kinase II delta 2 (CaMKIIδ(2)). Atherosclerosis (2012) 0.86
Detection of bcl-2 rearrangement in mucosa-associated lymphoid tissue lymphomas from patients with hepatitis C virus infection. Haematologica (2004) 0.86
Erratum to: (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Eur J Nucl Med Mol Imaging (2015) 0.84
A novel CDH1 germline missense mutation in a sporadic gastric cancer patient in north-east of Italy. Clin Exp Med (2012) 0.84
Hepatitis C virus (HCV) I hepatitis C virus (HCV) infection and lymphoproliferative disorders. Front Biosci (2005) 0.84
Morphological and metabolic changes in the nigro-striatal pathway of synthetic proteasome inhibitor (PSI)-treated rats: a MRI and MRS study. PLoS One (2013) 0.84
Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. Endocr Relat Cancer (2014) 0.84
IGKV3 proteins as candidate "off-the-shelf" vaccines for kappa-light chain-restricted B-cell non-Hodgkin lymphomas. Clin Cancer Res (2012) 0.83
Elevated B cell-activating factor of the tumour necrosis factor family in coeliac disease. Scand J Gastroenterol (2007) 0.83
Third Italian national survey on knowledge, attitudes, and sexual behaviour in relation to HIV/AIDS risk and the role of health education campaigns. Eur J Public Health (2006) 0.83
Pregnancy and human herpesvirus 8 reactivation in human immunodeficiency virus type 1-infected women. J Clin Microbiol (2006) 0.83
Low frequency of bcl-2 rearrangement in HCV-associated non-Hodgkin's lymphoma tissue. Leukemia (2003) 0.83
Second primary lymphoma or recurrence: a dilemma solved by VDJ rearrangement analysis. Leuk Lymphoma (2004) 0.83
KIR/HLA combination associated with the risk of complications in celiac disease. Int J Biol Markers (2011) 0.83
Interferon-based therapy for chronic hepatitis C: current and future perspectives. Hepat Mon (2010) 0.83
Lack of HCV infection in malignant cells refutes the hypothesis of a direct transforming action of the virus in the pathogenesis of HCV-associated B-cell NHLs. Tumori (2002) 0.83
Clonal CD27+ CD19+ B cell expansion through inhibition of FC gammaIIR in HCV(+) cryoglobulinemic patients. Ann N Y Acad Sci (2009) 0.83
Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization. Haematologica (2006) 0.82
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme. BJU Int (2014) 0.82
Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders. J Transl Med (2010) 0.82
Safety of shellfish and epidemiological pattern of enterically transmitted diseases in Italy. Int J Food Microbiol (2013) 0.81